155 related articles for article (PubMed ID: 36959048)
1. The EU-funded I
Prelaj A; Ganzinelli M; Trovo' F; Roisman LC; Pedrocchi ALG; Kosta S; Restelli M; Ambrosini E; Broggini M; Pravettoni G; Monzani D; Nuara A; Amat R; Spathas N; Willis M; Pearson A; Dolezal J; Mazzeo L; Sangaletti S; Correa AM; Aguaron A; Watermann I; Popa C; Raimondi G; Triulzi T; Steurer S; Lo Russo G; Linardou H; Peled N; Felip E; Reck M; Garassino MC
Clin Lung Cancer; 2023 Jun; 24(4):381-387. PubMed ID: 36959048
[TBL] [Abstract][Full Text] [Related]
2. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Ranganath H; Jain AL; Smith JR; Ryder J; Chaudry A; Miller E; Hare F; Valasareddy P; Seitz RS; Hout DR; Varga MG; Schweitzer BL; Nielsen TJ; Mullins J; Ross DT; Gandara DR; Vidal GA
BMC Cancer; 2022 Apr; 22(1):407. PubMed ID: 35421940
[TBL] [Abstract][Full Text] [Related]
3. The artificial intelligence and machine learning in lung cancer immunotherapy.
Gao Q; Yang L; Lu M; Jin R; Ye H; Ma T
J Hematol Oncol; 2023 May; 16(1):55. PubMed ID: 37226190
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
[TBL] [Abstract][Full Text] [Related]
6. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
7. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
8. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
[TBL] [Abstract][Full Text] [Related]
9. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
Ayers KL; Mullaney T; Zhou X; Liu JJ; Lee K; Ma M; Jones S; Li L; Redfern A; Jappe W; Liu Z; Goldsweig H; Yadav KK; Hahner N; Dietz M; Zimmerman M; Prentice T; Newman S; Veluswamy R; Wisnivesky J; Hirsch FR; Oh WK; Li SD; Schadt EE; Chen R
Oncologist; 2021 Jul; 26(7):e1226-e1239. PubMed ID: 33829580
[TBL] [Abstract][Full Text] [Related]
11. Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy.
Prelaj A; Boeri M; Robuschi A; Ferrara R; Proto C; Lo Russo G; Galli G; De Toma A; Brambilla M; Occhipinti M; Manglaviti S; Beninato T; Bottiglieri A; Massa G; Zattarin E; Gallucci R; Galli EG; Ganzinelli M; Sozzi G; de Braud FGM; Garassino MC; Restelli M; Pedrocchi ALG; Trovo' F
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053597
[TBL] [Abstract][Full Text] [Related]
12. 27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study.
Saltman DL; Varga MG; Nielsen TJ; Croteau NS; Lockyer HM; Jain AL; Vidal GA; Hout DR; Schweitzer BL; Seitz RS; Ross DT; Gandara DR
Clin Lung Cancer; 2023 Mar; 24(2):137-144. PubMed ID: 36564297
[TBL] [Abstract][Full Text] [Related]
13. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.
Prelaj A; Rebuzzi SE; Pizzutilo P; Bilancia M; Montrone M; Pesola F; Longo V; Del Bene G; Lapadula V; Cassano F; Petrillo P; Bafunno D; Varesano N; Lamorgese V; Mastrandrea A; Ricci D; Catino A; Galetta D
Clin Lung Cancer; 2020 Jul; 21(4):365-377.e5. PubMed ID: 32245624
[TBL] [Abstract][Full Text] [Related]
14. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
15. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
Li S; Zhang C; Pang G; Wang P
Front Immunol; 2020; 11():603157. PubMed ID: 33178229
[TBL] [Abstract][Full Text] [Related]
16. Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis.
Di Federico A; De Giglio A; Gelsomino F; Sperandi F; Melotti B; Ardizzoni A
J Natl Cancer Inst; 2023 Jan; 115(1):29-42. PubMed ID: 36322815
[TBL] [Abstract][Full Text] [Related]
17. Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression.
Stinchcombe TE; Miksad RA; Gossai A; Griffith SD; Torres AZ
Clin Lung Cancer; 2020 Sep; 21(5):389-394.e3. PubMed ID: 32409266
[TBL] [Abstract][Full Text] [Related]
18. Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer.
Yin X; Liao H; Yun H; Lin N; Li S; Xiang Y; Ma X
Semin Cancer Biol; 2022 Nov; 86(Pt 2):146-159. PubMed ID: 35963564
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
[TBL] [Abstract][Full Text] [Related]
20. Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer.
Bazhenova L; Kish J; Cai B; Caro N; Feinberg B
Cancer Treat Res Commun; 2022; 33():100637. PubMed ID: 36162323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]